By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
AmextaFinanceAmextaFinance
  • Home
  • News
  • Banking
  • Credit Cards
  • Loans
  • Mortgage
  • Investing
  • Markets
    • Stocks
    • Commodities
    • Crypto
    • Forex
  • Videos
  • More
    • Finance
    • Dept Management
    • Small Business
Notification Show More
Aa
AmextaFinanceAmextaFinance
Aa
  • Banking
  • Credit Cards
  • Loans
  • Dept Management
  • Mortgage
  • Markets
  • Investing
  • Small Business
  • Videos
  • Home
  • News
  • Banking
  • Credit Cards
  • Loans
  • Mortgage
  • Investing
  • Markets
    • Stocks
    • Commodities
    • Crypto
    • Forex
  • Videos
  • More
    • Finance
    • Dept Management
    • Small Business
Follow US
AmextaFinance > Investing > Amgen Stock Was a Winner in the Third Quarter. These Solar Shares Weren’t.
Investing

Amgen Stock Was a Winner in the Third Quarter. These Solar Shares Weren’t.

News Room
Last updated: 2023/09/30 at 11:04 AM
By News Room
Share
5 Min Read
SHARE

Contents
Top PerformersBottom Performers

A healthcare stock emerged as a clear winner during a tough third quarter for Wall Street. Shares of two solar companies, however, couldn’t escape the drubbing.

The following stocks were the best and worst performers in the three major indexes during the third quarter of 2023.

Top Performers

Amgen
(ticker: AMGN) was the best-performing stock in the
Dow Jones Industrial Average
 
in the third quarter, rising 21%, according to Dow Jones Market Data.

Shares of the biotechnology company received a boost after Amgen posted better-than-expected second-quarter earnings and revenue. The company also increased its forecast for revenue for 2023.

Arvind Sood, vice president of investor relations, said during the company’s earnings call back in August that Amgen “continued down the path of strong unit volume growth during the quarter that led to an improved outlook for the rest of the year.”

Then on Sept. 1, the Federal Trade Commission reached a deal with Amgen that approved the company’s $27.8 billion acquisition of
Horizon Therapeutics
(HZNP), with restrictions meant to limit the possibility of reduced competition to the biopharmaceutical industry.

Zions Bancorp
(ZION) was the top performer in the
S&P 500,
rising 30%. Second-quarter earnings at the lender beat Wall Street estimates as deposits rebounded. The rebound came after regional banks earlier in the year took a hit following the shutdowns of Silicon Valley Bank and
Signature Bank.

Citi analyst Keith Horowitz this week initiated coverage of Zions with a Buy rating. Horowitz said he expects the stock will benefit from a potential third-quarter outperformance to net interest income relative to expectations, plus subsequent positive revisions to the bank’s forecasts to that profitability metric.

Morgan Stanley analyst Manan Gosalia downgraded shares of Zions to Underweight from Equal Weight on Wednesday, but wrote in a research note that “after a 70%+ rally from May lows, ZION is now trading in-line with peers after having consistently been at a discount for the majority of 2023.”

American depositary receipts of
PDD Holdings
(PDD) led the
Nasdaq 100
in the quarter with a gain of 42%. The owner of online marketplace Temu reported second-quarter earnings of $1.44 a share on revenue of $7.2 billion, while Wall Street had expected $1 a share from revenue of $5.95 billion.

Shares of the Chinese company also benefited from a Bloomberg report in September that said Beijing was considering relaxing rules that limit foreign ownership in domestic publicly traded companies.

Bottom Performers

Walgreens Boots Alliance
(WBA) fell 22% in the third quarter and was the worst-performing stock in the Dow. The stock has declined 41% this year.

The retail pharmacy chain slashed its full-year profit outlook in June after it said demand for Covid-19 tests had dropped.

The stock took in a hit in July after Walgreens announced the departure of Chief Financial Officer James Kehoe. It fell further after Walgreens announced Sept. 1, that Chief Executive Rosalind Brewer was stepping down from the role she held since 2021.

SolarEdge Technologies
(SEDG) was the worst-performing stock in the S&P 500 during the quarter, tumbling 52%. Like other solar panel makers, the company has been hit as rising interest rates have made homeowners hesitate to borrow for expensive projects.

SolarEdge said in August that it expected third-quarter revenue of between $880 million and $920 million, lower than Wall Street estimates at the time of $1.05 billion.

Enphase Energy
(ENPH), a maker of microinverters that convert sunlight hitting solar panels into usable power, also got clobbered. It was the Nasdaq 100’s worst stock, falling 28%.

The company issued third-quarter revenue guidance that was below Wall Street consensus as solar-power demand declined.

Seaport Research Partners analyst Tom Curran, however, recently upgraded shares of Enphase to Buy from Neutral. He said the solar industry should begin to recover in 2024 as interest rates cool, suggesting that investors should get in on the stock early following a year of declines “to catch the sunrise.”

Write to Angela Palumbo at [email protected]

Read the full article here

News Room September 30, 2023 September 30, 2023
Share this Article
Facebook Twitter Copy Link Print
Leave a comment Leave a comment

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Finance Weekly Newsletter

Join now for the latest news, tips, and analysis about personal finance, credit cards, dept management, and many more from our experts.
Join Now
Why Trump Is Targeting Federal Reserve Chair Jerome Powell

Watch full video on YouTube

Trump to offer some tariff exemptions as the cost of groceries climbs

Watch full video on YouTube

Wall Street hits back at Trump’s plan to limit interest on credit cards

Major US banks have lashed out at Donald Trump’s proposal to cap…

Franklin Moderate Allocation Fund Q3 2025 Commentary

Franklin Resources, Inc. is a global investment management organization with subsidiaries operating…

Forget Injections. Now You Can Just Take Pills For Weight Loss

Watch full video on YouTube

- Advertisement -
Ad imageAd image

You Might Also Like

Investing

Why Home Builders Are Bouncing Today—and Why Their Stocks Are Good Buys

By News Room
Investing

This Beaten-Down Industrial Stock Wants to Call America Home. Why It’s Time to Buy.

By News Room
Investing

These 8 Dividend Aristocrats Can Protect Your Portfolio in a Downturn

By News Room
Investing

Some Lenders Benefit From SBA’s Troubled Loan Program

By News Room
Investing

Social Security Is in Turmoil. Should You Lock In Benefits Now?

By News Room
Investing

Hims & Hers Stock Is Due for a Crash Diet. The GLP-1 Surge Is Fading Fast.

By News Room
Investing

Opinion: The stock-market selloff isn’t over yet. Here are 4 reasons why.

By News Room
Investing

With Trump’s tariffs paused, ‘Big Three’ automakers may race to build inventories

By News Room
Facebook Twitter Pinterest Youtube Instagram
Company
  • Privacy Policy
  • Terms & Conditions
  • Press Release
  • Contact
  • Advertisement
More Info
  • Newsletter
  • Market Data
  • Credit Cards
  • Videos

Sign Up For Free

Subscribe to our newsletter and don't miss out on our programs, webinars and trainings.

I have read and agree to the terms & conditions
Join Community

2023 © Indepta.com. All Rights Reserved.

YOUR EMAIL HAS BEEN CONFIRMED.
THANK YOU!

Welcome Back!

Sign in to your account

Lost your password?